Europe Medical Cannabis Market Growth, Size, Trends, Demand, Revenue, Share and Future Outlook
Europe Medical Cannabis Market Size- By Species, By Derivative, By Application, By End User, By Route of Administration- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: May-2024 | Report ID: PHAR2408 | Pages: 1 - 153 | Formats*: |
| Category : Pharmaceutical | |||
Europe Medical Cannabis Market Introduction and Overview
According to SPER Market Research, the Europe Medical Cannabis Market is estimated to reach USD 58.11 billion by 2033 with a CAGR of 24.3%.
The report includes an in-depth analysis of the Europe Medical Cannabis Market, including market size and trends, product mix, distribution channels, and supplier analysis. The cannabis plant, which belongs to the Cannabaceae family, is the source of the psychoactive substance known as cannabis. It is used medicinally and has been for a while. Treatments for chronic pain, cancer, depression, diabetes, glaucoma, arthritis, migraines, AIDS, and Alzheimer's are just a few of the conditions for which it is used.
- Tilray declared in May 2020 that it had obtained GMP certification in accordance with EU regulations, enabling the establishment to produce medical cannabis extracts on-site and export completed medical cannabis products. This facilitated the company's growth.
- Sanity Group GmbH, a division of Sanity Medical, and Telaleaf, a telemedicine platform, signed a partnership in February 2022 to advance telemedicine in cannabis therapy in Germany.
Market Opportunities and Challenges
Opportunities: One of the primary factors supporting a favorable market outlook is the rising incidence of chronic illnesses like cancer, arthritis, Alzheimer's, and migraines. Moreover, the industry is expanding due to the increased use of medical cannabis for pain relief. To numb pain receptors and give patients immediate comfort, it is typically smoked, inhaled, taken orally, or used topically. Furthermore, the legalization of medicinal marijuana in Europe has improved the products' accessibility through medical facilities and licensed outlets, which has fueled market expansion. It is projected that additional factors will propel the market, such as intensive research and development (R&D) efforts aimed at optimizing the use of cannabinoids and advancements in the healthcare infrastructure.
Challenges: Effects of Cannabis Use and Overuse: Short- and Long-Term Side Effects Following the use of the implants and drugs, orthopedic professionals note certain hazards. Complications from surgery or an implant gone wrong are delivered by the knee replacement surgeries. Among the most serious side effects following knee surgery is a loose implant; discomfort is the most frequent one. Serious falls, instability, and fractures of the bones can result from loosening. Surgery for revision is necessary for almost all major problems. Mechanical concerns, physical pain, and loosening of the knee implant are the risks.
Market Competitive Landscape
The Medical Cannabis market in Europe is moderately consolidated. Some of the market key players are Tilray, Althea Company Pty Ltd (A subsidiary of Althea Group Holdings Limited), PharmaHemp, Aurora Cannabis Inc., CANOPY GROWTH CORPORATION.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Species, By Derivative, By Application, By End Use, By Route of Administration |
| Regions covered | UK, France, Germany, Italy, Spain, Rest of Europe |
| Companies Covered | Tilray, Althea Company Pty Ltd (A subsidiary of Althea Group Holdings Limited), Jazz Pharmaceuticals, Inc., EcoGen Biosciences, GRASS & CO., PharmaHemp, Aurora Cannabis Inc., CANOPY GROWTH CORPORATION, CANNARAY, and Sanity Group GmbH among others |
COVID-19 Impact on Europe Medical Cannabis Market
The COVID-19 epidemic had a major effect on Europe's medical cannabis business, posing both opportunities and obstacles. Lockdowns and other regulations originally caused supply chains to break and made it more difficult for patients to obtain medical cannabis products, but they also led to changes in regulations and a rise in the adoption of telemedicine consultations, which made medical cannabis more widely accessible to those in need. Additionally, some European nations accelerated the legalization or development of medicinal cannabis programs in an effort to profit from the industry's potential economic benefits as governments looked for cash sources to lessen economic downturns.
Key Target Audience:
- Healthcare Professionals
- Patients and Caregivers
- Government Regulators and Policymakers
- Medical Cannabis Producers and Distributors
- Pharmaceutical Companies
- Research Institutions and Academia
Our in-depth analysis of the Europe Medical Cannabis Market includes the following segments:
| By Species: |
|
| By Derivative: |
|
| By Application: |
|
| By End Use: |
|
| By Route of Administration: |
|
Key Topics Covered in the Report:
- Europe Medical Cannabis Market Size (FY’2024-FY’2033)
- Overview of Europe Medical Cannabis Market
- Segmentation of Europe Medical Cannabis Market By Species (Indica, Sativa, Hybrid)
- Segmentation of Europe Medical Cannabis Market By Derivative (Cannabidiol Tetrahydrocannabinol Others)
- Segmentation of Europe Medical Cannabis Market By Application (Cancer, Arthritis, Migraine, Epilepsy, Others)
- Segmentation of Europe Medical Cannabis Market By End Use (Pharmaceutical Industry, Research and Development Centers, Others)
- Expansion Analysis of Europe Medical Cannabis Market
- Problems and Obstacles in Europe Medical Cannabis Market
- Competitive Landscape in the Europe Medical Cannabis Market
- Impact of COVID-19 and Demonetization on Europe Medical Cannabis Market
- Details on Current Investment in Europe Medical Cannabis Market
- Competitive Analysis of Europe Medical Cannabis Market
- Prominent Players in the Europe Medical Cannabis Market
- SWOT Analysis of Europe Medical Cannabis Market
- Europe Medical Cannabis Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Europe Medical Cannabis Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Medical Cannabis Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Medical Cannabis Market
7. Europe Medical Cannabis Market, By Species (USD Million) 2020-2033
7.1. Europe Medical Cannabis Market Size, Share and Forecast, By Species, 2020-20267.2. Europe Medical Cannabis Market Size, Share and Forecast, By Species, 2027-20337.3. Indica7.4. Sativa7.5. Hybrid
8. Europe Medical Cannabis Market, By Derivative (USD Million) 2020-2033
8.1. Europe Medical Cannabis Market Size, Share and Forecast, By Derivative, 2020-20268.2. Europe Medical Cannabis Market Size, Share and Forecast, By Derivative, 2027-20338.3. Cannabidiol (CBD)8.4. Tetrahydrocannabinol (THC)8.5. Others
9. Europe Medical Cannabis Market, By Application (USD Million) 2020-2033
9.1. Europe Medical Cannabis Market Size, Share and Forecast, By Application, 2020-20269.2. Europe Medical Cannabis Market Size, Share and Forecast, By Application, 2027-20339.3. Cancer9.4. Arthritis9.5. Migraine9.6. Epilepsy9.7. Others
10. Europe Medical Cannabis Market, By End Use (USD Million) 2020-2033
10.1. Europe Medical Cannabis Market Size, Share and Forecast, By End Use, 2020-202610.2. Europe Medical Cannabis Market Size, Share and Forecast, By End Use, 2027-203310.3. Pharmaceutical Industry10.4. Research and Development Centers10.5. Others
11. Europe Medical Cannabis Market, By Route of Administration (USD Million) 2020-2033
11.1. Europe Medical Cannabis Market Size, Share and Forecast, By Route of Administration, 2020-202611.2. Europe Medical Cannabis Market Size, Share and Forecast, By Route of Administration, 2027-203311.3. Oral Solutions and Capsules11.4. Smoking11.5. Vaporizers11.6. Topicals11.7. Others
12. Europe Medical Cannabis Market Forecast, 2020-2033 (USD Million)
12.1. Europe Medical Cannabis Market Size and Market Share
13. Europe Medical Cannabis Market, By Region, 2020-2033 (USD Million)
13.1. Europe Medical Cannabis Market Size and Market Share By Region (2020-2026)13.2. Europe Medical Cannabis Market Size and Market Share By Region (2027-2033)13.3. France13.4. Germany13.5. Italy13.6. United Kingdom13.7. Rest of Europe
14. Company Profile
14.1. Althea Company Pty Ltd14.1.1. Company details14.1.2. Financial outlook14.1.3. Product summary14.1.4. Recent developments14.2. Aurora Cannabis Inc.14.2.1. Company details14.2.2. Financial outlook14.2.3. Product summary14.2.4. Recent developments14.3. CANOPY GROWTH CORPORATION14.3.1. Company details14.3.2. Financial outlook14.3.3. Product summary14.3.4. Recent developments14.4. CANNARAY14.4.1. Company details14.4.2. Financial outlook14.4.3. Product summary14.4.4. Recent developments14.5. EcoGen Biosciences14.5.1. Company details14.5.2. Financial outlook14.5.3. Product summary14.5.4. Recent developments14.6. GRASS & CO.14.6.1. Company details14.6.2. Financial outlook14.6.3. Product summary14.6.4. Recent developments14.7. Jazz Pharmaceuticals, Inc.14.7.1. Company details14.7.2. Financial outlook14.7.3. Product summary14.7.4. Recent developments14.8. PharmaHemp14.8.1. Company details14.8.2. Financial outlook14.8.3. Product summary14.8.4. Recent developments14.9. Sanity Group GmbH14.9.1. Company details14.9.2. Financial outlook14.9.3. Product summary14.9.4. Recent developments14.10. Tilray14.10.1. Company details14.10.2. Financial outlook14.10.3. Product summary14.10.4. Recent developments14.11. Others
17. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
"Surgery for revision is necessary for almost all major problems. Mechanical concerns, physical pain, and loosening of the knee implant are the risks.
"
Europe Medical Cannabis Market is projected to reach USD 58.11 billion by 2033, growing at a CAGR of 24.3% during the forecast period.
Europe Medical Cannabis Market size from 2022. The Market is expected to reach USD 58.11 billion by 2033, at a CAGR of 24.3% during the forecast period.
Europe Medical Cannabis Market CAGR of 24.3% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Europe Medical Cannabis Market size is 58.11 billion from 2024 to 2033.
Europe Medical Cannabis Market Segment is covered By Species, By Derivative, By Application, By End Use, By Route of Administration
The Europe anticipated to have the highest market share in the Europe Medical Cannabis Market.
The key players in the market include Companies Covered Tilray, Althea Company Pty Ltd (A subsidiary of Althea Group Holdings Limited), Jazz Pharmaceuticals, Inc., EcoGen Biosciences, GRASS & CO., PharmaHemp, Aurora Cannabis Inc., CANOPY GROWTH CORPORATION, CANNARAY, and Sanity Group GmbH among others.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
